LogicBio Therapeutics (NASDAQ:LOGC) Cut to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of LogicBio Therapeutics (NASDAQ:LOGCGet Rating) from a buy rating to a hold rating in a report published on Tuesday morning, Zacks.com reports.

According to Zacks, “LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company’s technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts. “

LOGC has been the topic of a number of other research reports. Chardan Capital lowered their target price on LogicBio Therapeutics from $16.00 to $6.00 and set a hold rating on the stock in a report on Wednesday, February 2nd. William Blair upgraded LogicBio Therapeutics from a market perform rating to an outperform rating in a report on Monday, May 9th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of Buy and an average target price of $9.15.

Shares of NASDAQ:LOGC opened at $0.43 on Tuesday. The business’s fifty day moving average price is $0.63 and its two-hundred day moving average price is $1.65. The stock has a market cap of $14.17 million, a PE ratio of -0.35 and a beta of 1.51. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.84 and a current ratio of 2.84. LogicBio Therapeutics has a one year low of $0.34 and a one year high of $5.19.

LogicBio Therapeutics (NASDAQ:LOGCGet Rating) last announced its earnings results on Friday, March 4th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. The firm had revenue of $2.03 million for the quarter, compared to analysts’ expectations of $2.00 million. LogicBio Therapeutics had a negative return on equity of 95.00% and a negative net margin of 739.91%. As a group, equities research analysts predict that LogicBio Therapeutics will post -1.11 earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC purchased a new position in shares of LogicBio Therapeutics in the 1st quarter worth $312,000. Acadian Asset Management LLC purchased a new position in shares of LogicBio Therapeutics in the 1st quarter worth $32,000. Goldman Sachs Group Inc. raised its position in shares of LogicBio Therapeutics by 1,105.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 508,475 shares of the company’s stock worth $1,175,000 after buying an additional 466,289 shares during the period. Virtu Financial LLC purchased a new position in shares of LogicBio Therapeutics in the 4th quarter worth $40,000. Finally, Samlyn Capital LLC raised its position in shares of LogicBio Therapeutics by 2.5% in the 4th quarter. Samlyn Capital LLC now owns 1,511,417 shares of the company’s stock worth $3,492,000 after buying an additional 37,309 shares during the period. Institutional investors and hedge funds own 55.20% of the company’s stock.

About LogicBio Therapeutics (Get Rating)

LogicBio Therapeutics, Inc, a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues.

Featured Articles

Get a free copy of the Zacks research report on LogicBio Therapeutics (LOGC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for LogicBio Therapeutics (NASDAQ:LOGC)

Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.